CoChat

A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease

Open access
Tabrez, Shams, R. Jabir, Nasimudeen, Shakil, Shazi, H. Greig, Nigel, Alam, Qamre, M. Abuzenadah, Adel, A. Damanhouri, Ghazi, A. Kamal, Mohammad · 2012 · CNS & Neurological Disorders - Drug Targets
Cited by 150

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Parkinson's disease (PD) is a common chronic progressive neurodegenerative disorder in elderly people. A consistent neurochemical abnormality in PD is degeneration of dopaminergic neurons in substantia nigra pars compacta, leading to a reduction of striatal dopamine (DA) levels. As tyrosine hydroxylase (TH) catalyses the formation of L-dihydroxyphenylalanine (L-DOPA), the rate-limiting step in the biosynthesis of DA, the disease can be considered as a TH-deficiency syndrome of the striatum. Problems related to PD usually build up when vesicular storage of DA is altered by the presence of either α-synuclein protofibrils or oxidative stress. Phosphorylation of three physiologically-regulated specific sites of N-terminal domain of TH is vital in regulating its kinetic and protein interaction. The concept of physiological significance of TH isoforms is another interesting aspect to be explored further for a comprehensive understanding of its role in PD. Thus, a logical and efficient strategy for PD treatment is based on correcting or bypassing the enzyme deficiency by the treatment with L-DOPA, DA agonists, inhibitors of DA metabolism or brain grafts with cells expressing a high level of TH. Neurotrophic factors are also attracting the attention of neuroscientists because they provide the essential neuroprotective and neurorestorative properties to the nigrostriatal DA system. PPAR-γ, a key regulator of immune responses, is likewise a promising target for the treatment of PD, which can be achieved by the use of agonists with the potential to impact the expression of pro- and anti-inflammatory cytokines at the transcriptional level in immune cells via expression of TH. Herein, we review the primary biochemical and pathological features of PD, and describe both classical and developing approaches aimed to ameliorate disease symptoms and its progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/187152712800792785

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 150

Metadata

Authors
Tabrez, S., R. Jabir, N., Shakil, S., H. Greig, N., Alam, Q., M. Abuzenadah, A., A. Damanhouri, G., & A. Kamal, M.
Venue
CNS & Neurological Disorders - Drug Targets
Published
2012-05-01
Volume
11
Issue
4
Pages
395-409
ISSN
  • 1568-007X (ISSN-L)
  • 1871-5273
OpenAlex
W2107683010
Cited by
150
References
38
FWCI
3.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease. https://app.cochat.ai/papers/10.2174/187152712800792785
The paper
Tabrez, S., R. Jabir, N., Shakil, S., H. Greig, N., Alam, Q., M. Abuzenadah, A., A. Damanhouri, G., & A. Kamal, M. (2012). A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/187152712800792785

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.